SCHEMBL8306334

SCHEMBL8306334

Cc1ccc(-n2ccncc2=O)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.47
NPSR1 Q6W5P4 1/20 0.44
HCAR1 Q9BXC0 1/20 0.43
ALDH1A1 P00352 5/20 0.43
COMT P21964 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
HTT P42858 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 3/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
GRM1 Q13255 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8306336 0.84 MAPK14 (0.43) MAPK14NPSR1MAPT
SCHEMBL8306420 0.84 MAPK14 (0.43) MAPK14HCAR1ALDH1A1HTTMEN1
SCHEMBL14502105 0.81 MAPK14 (0.40) MAPK14ALDH1A1MAPTMEN1KMT2A
SCHEMBL8266914 0.78 F2 (0.42) MAPK14NPSR1HCAR1ALDH1A1TDP1
SCHEMBL8306577 0.75 NPSR1 (0.47) NPSR1HCAR1ALDH1A1COMTTDP1
SCHEMBL3304568 0.70 ALDH1A1 (0.52) MAPK14NPSR1HCAR1ALDH1A1COMT
SCHEMBL8150237 0.70 ALKBH5 (0.43) MAPK14ALDH1A1TDP1KDM4EMAPT
SCHEMBL8262170 0.70 CYP3A4 (0.45) MAPK14ALDH1A1MAPTCYP3A4CYP2C19
SCHEMBL1885632 0.69 CYP3A4 (0.46) NPSR1ALDH1A1TDP1MAPTMEN1
SCHEMBL17666283 0.69 NPSR1 (0.44) NPSR1HCAR1ALDH1A1COMTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
WO-2004082687-A1 LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS F12, F2, PEPD MAPK14 2758/4885NPSR1 2220/4885HCAR1 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.